Related Experiment Video

Updated: Aug 19, 2026

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection
09:01

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

Published on: December 10, 2013

[RSV infections in children including managed cases in premature babies]

K Nowicka1, B Gierowska-Bogusz, K Polak

  • 1Klinika Neonatologii, Instytut Matki i Dziecka, Kasprzaka 17a, 01-211 Warszawa, Poland.

Medycyna Wieku Rozwojowego
|May 11, 2002
PubMed

Insights

Respiratory Syncytial Virus (RSV) infection poses severe risks to premature neonates. Vaccination development is crucial for preventing severe RSV disease in this vulnerable population.

Area of Science:

  • Neonatology
  • Infectious Diseases
  • Pediatric Respiratory Illnesses

Context:

  • Assessed Respiratory Syncytial Virus (RSV) infection cases in a Neonatology Department during 2000/2001.
  • Focused on epidemiology, pathology, pathogenesis, clinical course, treatment, and prevention of RSV in neonates.
  • Identified 5 cases of RSV infection among premature infants.

Purpose:

  • To analyze the characteristics and outcomes of RSV infections in a neonatal intensive care setting.
  • To identify risk factors and prognostic indicators for severe RSV disease in preterm infants.
  • To discuss current treatment and prevention strategies for RSV in neonates.

Summary:

  • Two infants experienced severe RSV infection with respiratory insufficiency, while two others had moderate symptoms managed with n-CPAP.
  • One case presented with mild symptoms; prematurity, young age, cardiac/lung pathology, and immunodeficiency were negative prognostic factors.
  • Maternal transmission was suspected as the source of infection in one instance.

Impact:

  • Highlights the significant morbidity associated with RSV in premature neonates.
  • Emphasizes the need for improved preventive measures, particularly vaccination, for high-risk infants.
  • Informs clinical management and public health strategies for RSV prevention in neonatal populations.

More Related Videos

An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay09:14

An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay

Published on: January 26, 2019

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses11:48

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Viral Meningitis01:18

Viral Meningitis

Viral meningitis is the most common form of meningitis and is often referred to as aseptic meningitis to indicate the absence of bacterial involvement. It is generally milder than bacterial meningitis, with symptoms including fever, headache, stiff neck, drowsiness, nausea, photophobia, and vomiting. Rarely, more severe manifestations or death may occur. Common causative agents include enteroviruses, particularly coxsackie A and B viruses and echoviruses, all members of the Enterovirus genus...
Cytomegalovirus Disease01:27

Cytomegalovirus Disease

Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...